List view / Grid view
11 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®...
11 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...
10 June 2014 | By Novo Nordisk
Novo Nordisk, will unveil 63 abstracts containing safety and efficacy data from our class-leading portfolio of diabetes products at the 74th Annual Scientific Sessions of the American Diabetes Association...
10 June 2014 | By Novartis
The Novartis Foundation for Sustainable Development and Netherlands Leprosy Relief announced their collaboration with national leprosy programs and other International Federation of Anti-Leprosy Associations...
10 June 2014 | By Amgen
Amgen announced the appointment of David W. Meline as executive vice president and chief financial officer, effective July 21, 2014...
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
9 June 2014 | By Merck
Merck and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. He will continue to report to Lamberto Andreotti, chief executive officer. In addition to his current responsibilities as chief commercial officer, Caforio…
6 June 2014 | By Merck
Merck announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
6 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome...
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
5 June 2014 | By The European Medicines Agency
European regulatory authorities have finalised their assessment of reported non-compliance with Good Manufacturing Practice at Ranbaxy Laboratories’ manufacturing site...
4 June 2014 | By The European Medicines Agency
The European Medicines Agency has published a revised guideline on the acceptability of names for human medicines processed through the centralised procedure...
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
4 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV). Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy...
